Top Markets
Coin of the day
Neovacs S.A. Neovacs S.A.

Neovacs S.A.

ALNEV
株式のランク #21228
Neovacs S.A., a biotechnology company, focuses on the development of... Neovacs S.A., a biotechnology company, focuses on the development of therapeutic vaccines for the treatment of autoimmune, inflammatory, allergy, and cancer diseases in France. It develops treatments for chronic autoimmune and inflammatory diseases using its proprietary Kinoid technology. The company's product pipeline includes IFNa Kinoid, an anti-interferon alpha vaccine that is in Phase IIb clinical trial for the treatment of systemic lupus erythematosus; Phase IIa clinical trial for the treatment of dermatomyositis; and preclinical stage for the treatment of diabetes. It is also developing VEGF-Kinoid, which is in preclinical stage for the treatment of age-related macular degeneration and solid tumors; and IL-4/IL-13 Kinoid that is in preclinical stage for the treatment of allergies. The company has a collaboration with the Sunnybrook Research Institute for preclinical development of VEGF Kinoid to treat colorectal and ovarian cancer. Neovacs S.A. was founded in 1993 and is based in Paris, France.
株価
$0.00047446
時価総額
$82.80
変化(1日)
0.00%
変化(1年)
-98.16%
FR
取引 Neovacs S.A. (ALNEV)

カテゴリー

Neovacs S.A.(ALNEV)の利益
Dec 2024 時点の利益 TTM: $-35.33M
Neovacs S.A. の最新の財務報告によると、同社の現在の利益は $-35.33M です。2023 年には $-10.63M の利益を上げ、これは 2022 年の利益 $-4.66M と 減少 です。このページに表示されている利益は、利息および税引き前利益、すなわち EBIT です。
Neovacs S.A. の利益の推移(2007 〜 2026)
各年末の利益
利益 変化
2026 (TTM) $-35.33M 0.00%
2024 $-35.33M 232.17%
2023 $-10.63M 128.13%
2022 $-4.66M -67.15%
2021 $-14.19M 74.31%
2020 $-8.14M -22.00%
2019 $-10.44M -33.00%
2018 $-15.58M -31.17%
2017 $-22.63M 24.13%
2016 $-18.23M 131.65%
2015 $-7.87M -33.75%
2014 $-11.88M 7.75%
2013 $-11.03M 0.62%
2012 $-10.96M -12.83%
2011 $-12.57M -8.71%
2010 $-13.77M 14.01%
2009 $-12.08M 72.06%
2008 $-7.02M -9.80%
2007 $-7.78M 0.00%
同業他社の利益
企業 利益 利益の差
$20.51B -58,146.44%
DK
$4.64B -13,244.00%
US
$5.23B -14,907.10%
US
$2.14B -6,151.40%
BE
$1.45B -4,207.73%
NL